Publications by authors named "Jeffrey Axler"

Claim this Profile
M
Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial.
Marc Ferrante, Peter M Irving, Maria T Abreu, Jeffrey Axler, Xiang Gao

J Crohns Colitis· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel Microbial-Based Immunotherapy Approach for Crohn's Disease.
Simon Sutcliffe, Shirin Kalyan, Jim Pankovich, Jenny M H Chen, Rashieda Gluck, Jeffrey Axler

Front Med (Lausanne)· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis.
Brian G Feagan, Stefan Schreiber, Douglas C Wolf, Jeffrey L Axler, Arpeat Kaviya

Inflamm Bowel Dis· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum: Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial.
David T Rubin, Russell D Cohen, William J Sandborn, Gary R Lichtenstein, Jeffrey Axler

J Crohns Colitis· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial.
David T Rubin, Russell D Cohen, William J Sandborn, Gary R Lichtenstein, Jeffrey Axler

J Crohns Colitis· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Vedolizumab in Ulcerative Colitis and Crohn's Disease Patients Stratified by Age.
Vijay Yajnik, Nabeel Khan, Marla Dubinsky, Jeffrey Axler, Alexandra James

Adv Ther· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
Brian G Feagan, Paul Rutgeerts, Bruce E Sands, Stephen Hanauer, Jean-Frédéric Colombel, Jeffrey Axler

N Engl J Med· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis